Corbus Pharmaceuticals Holdings, Inc. (CRBP) - 10-Q Summary
Business Context and Reporting Period
Company: Corbus Pharmaceuticals Holdings, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Corbus is a clinical-stage biopharmaceutical company focused on oncology and obesity. Its primary pipeline assets include CRB-701 (an antibody-drug conjugate for Nectin-4-expressing tumors) and CRB-913 (a CB1 inverse agonist for obesity). The company has no product revenue and relies on equity financing and license agreements.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(35,037) | $(58,006) | $(34,640) |
| Net Loss Per Share | $(1.81) | $(3.04) | $(2.83) |
| Operating Expenses | $36,190 | $60,494 | $38,927 |
| Research & Development (R&D) | $31,175 | $50,994 | $30,829 |
| General & Administrative (G&A) | $5,015 | $9,500 | $8,098 |
| Cash & Cash Equivalents | $23,370 | $23,370 | $28,492 (Dec 31, 2025) |
| Investments | $94,571 | $94,571 | $134,777 (Dec 31, 2025) |
| Total Liquidity (Cash + Investments) | $117,941 | $117,941 | $163,269 (Dec 31, 2025) |
| Accumulated Deficit | $(613,436) | $(613,436) | $(555,430) (Dec 31, 2025) |
Material Changes vs. Prior Period
- Increased Net Loss: Net loss for the six months ended June 30, 2026, increased to $58.0 million from $34.6 million in the same period in 2025. This represents a 67% increase year-over-year.
- R&D Expense Surge: R&D expenses rose 65% year-over-year to $51.0 million. This was primarily driven by a $10.0 million development milestone payment to CSPC for CRB-701 in April 2026 and increased clinical trial costs for CRB-701 and CRB-913.
- CRB-601 Deprioritization: Expenses for the CRB-601 program decreased significantly ($4.4 million reduction YTD) as the company deprioritized the program and ceased patient enrollment.
- Liquidity Reduction: Total cash, cash equivalents, and investments decreased from approximately $163.3 million at year-end 2025 to $117.9 million at June 30, 2026, due to operating burn and investment maturities.
- Financing Activity: The company raised approximately $9.1 million in net proceeds from the sale of common stock under its Open Market Sale Agreement during the first six months of 2026.
Outlook, Risks, and Management Commentary
- Clinical Progress:
- CRB-701: Received Fast Track designation for cervical cancer and HNSCC. The registrational study (TEMPO-1) in 2L OPSCC is expected to begin enrollment in September 2026. Data from the Phase 1/2 Western study was presented at ASCO 2026 showing robust activity.
- CRB-913: Completed Phase 1a and Phase 1b (CANYON-1) studies. Data reporting is expected in September 2026. Early results showed weight loss with a favorable GI safety profile.
- Liquidity Outlook: Management expects current cash and investments of approximately $117.9 million to be sufficient to meet operating and capital requirements for at least twelve months from the filing date (August 2026).
- Capital Needs: The company anticipates continuing to incur significant operating losses and will require additional financing to fund clinical trials and operations. Future funding may come from equity offerings, debt, or collaborations.
- Risks: Key risks include the failure to raise additional capital, delays in clinical trials, inability to obtain regulatory approval, and the high cost of development. The company has an accumulated deficit of $613.4 million.
- Subsequent Events:
- Sold an additional 738,707 shares under the Open Market Sale Agreement between July 1 and the filing date, raising ~$6.7 million.
- Appointed Leonardo Viana Nicacio, MD, as Chief Medical Officer (effective August 3, 2026) with a $2.1 million inducement award.
Investor Verification Checklist
- Cash Runway: Verify the $117.9 million liquidity figure against current burn rates to confirm the 12-month runway assertion.
- Milestone Payments: Confirm the $10.0 million CSPC milestone payment was expensed in Q2 2026 and review remaining potential milestone obligations ($120M development + $555M commercial).
- CRB-701 Trial Enrollment: Monitor the start date of the TEMPO-1 registrational study (expected September 2026) and enrollment rates.
- CRB-913 Data Readout: Await the September 2026 data release from the CANYON-1 Phase 1b study to validate efficacy and safety claims.
- Dilution Risk: Track future equity issuances under the Open Market Sale Agreement (approx. $52.8M remaining capacity as of filing) and potential new capital raises.